To include your compound in the COVID-19 Resource Center, submit it here.

Neoantigens for all

How Nouscom is creating personalized and off-the-shelf neoantigen vaccines

Nouscom AG has a simplified neoantigen platform that cuts production time, designed to deliver vaccines to cancer patients more quickly than the standard methods. With a two-pronged approach, the company is developing both personalized vaccines and off-the-shelf ones that could become first in class.

Nouscom’s platform is unique in using replication-deficient Great Apes Adenovirus vectors as a prime and Modified Vaccinia Virus Ankara vectors as a boost,

Read the full 664 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers